$A

Agilent Technologies said European regulators certified its PD-L1 IHC 22C3 pharmDx test (Code SK006) as a companion diagnostic for epithelial ovarian, fallopian tube, and primary peritoneal carcinoma, enabling identification of patients who may benefit from Merck’s Keytruda. The approval is the assay’s eighth CE-marked indication in the EU. The article compares Agilent with Danaher’s Leica unit and valuation metrics (Agilent ~20.58 forward P/E, Danaher ~22.88).

Agilent Technologies (NYSE: A) said the EU approved its PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic for epithelial ovarian, fallopian tube, or primary peritoneal carcinoma to identify patients whose tumors express PD-L1 and may be eligible for Merck’s KEYTRUDA (pembrolizumab). Agilent said it is the eighth CE-marked indication for this test.

TheFly (July 6) reported Evercore ISI raised its Agilent Technologies (NYSE:A) price target to $148 from $144 and kept an Outperform rating, citing stable procedure volumes and capital spending across MedTech, Life Sciences Tools, and Diagnostics. Agilent (July 1) also launched Agilent xCELLigence RTCA eSight AI, an AI-enabled module for label-free imaging analysis.

AGILENT TECHNOLOGIES, INC. (A) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.2 2 d75293dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 AGILENT TECHNOLOGIES, INC. (as Obligor) and CITIBANK, N.A. (as Trustee) Fourth Supplemental Indenture Dated as of June 25, 2026 4.900% Senior Notes due 2032 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 SECTION 1.01 Definitions

The article says the U.S. healthcare sector lagged the market for three straight years, returning 0.3% (2023), 0.9% (2024) and 12.5% (2025), and is down 1.62% YTD in 2026 vs. the S&P 500’s 10.35% gain. Analysts cite AI-focused capital shifts and valuation gaps. It lists 10 healthcare stocks screened for ≥20% upside; examples include Elanco (ELAN) with a TD Cowen price target raised to $32 and Agilent (A) with a Piper Sandler $150 target plus an OpenAI/BCG AI collaboration.

Agilent Technologies (A), a $37.5B large-cap life sciences and diagnostics company, has outperformed the Nasdaq over three months, rising 16.2% vs. the Nasdaq’s 13.1%, though it lags over 52 weeks (16.1% vs. 31.1%) and is slightly down YTD. After May 27 better-than-expected Q2 results (revenue $1.8B, +10% YoY; adj. EPS $1.49), shares jumped 16.9%. Analysts rate it “Strong Buy” (17 analysts) with a $163.13 mean target.

Agilent Technologies (NYSE: A) saw multiple analyst rating and target changes. HSBC cut its target to $165 (buy), TD Cowen raised to $155 (buy), Barclays to $145 (overweight), Wells Fargo to $160 (overweight), and Bank of America set $145 (buy). Royal Bank of Canada started coverage with an outperform $153 target. Agilent also announced a $0.255 quarterly dividend, payable July 22 to holders of record June 30.

Impax Global Environmental Markets Fund’s Q1 2026 investor letter said Agilent Technologies (NYSE:A) fell during the quarter despite results and guidance ahead of expectations, citing market concerns over speculation about a potential QIAGEN acquisition. The fund reported outperforming the MSCI ACWI. Agilent reported $1.83B revenue in Q2 FY2026.

Dolsten Mikael sold 1,600 shares of AGILENT TECHNOLOGIES, INC. (A) at $135.42 ($0.22M total) on 2026-05-29.

US Q1 GDP was revised to +1.6% (q/q annualized) from +2.0% expected; Q1 personal consumption was cut to +1.4%, while core PCE rose to a 3-year high of +4.4%. Apr new home sales fell 6.2% m/m to 622k. Stocks rebounded after Axios reported a preliminary US-Iran deal to extend the ceasefire 60 days and begin nuclear talks. Fed hawkishness weighed; markets priced a 3% chance of a 25 bp June cut.